Segall Bryant & Hamill LLC Buys 24,170 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Segall Bryant & Hamill LLC lifted its position in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 117.7% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 44,701 shares of the medical research company's stock after buying an additional 24,170 shares during the quarter. Segall Bryant & Hamill LLC's holdings in Thermo Fisher Scientific were worth $27,651,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Capital World Investors raised its holdings in shares of Thermo Fisher Scientific by 10.0% in the 1st quarter. Capital World Investors now owns 13,493,852 shares of the medical research company's stock valued at $7,842,762,000 after purchasing an additional 1,231,059 shares during the period. Price T Rowe Associates Inc. MD lifted its position in shares of Thermo Fisher Scientific by 1.6% in the first quarter. Price T Rowe Associates Inc. MD now owns 10,054,621 shares of the medical research company's stock valued at $5,843,848,000 after buying an additional 156,675 shares during the last quarter. Capital Research Global Investors increased its holdings in shares of Thermo Fisher Scientific by 1.5% during the 1st quarter. Capital Research Global Investors now owns 8,113,137 shares of the medical research company's stock worth $4,715,436,000 after acquiring an additional 123,523 shares during the last quarter. Ameriprise Financial Inc. raised its stake in Thermo Fisher Scientific by 32.2% in the 2nd quarter. Ameriprise Financial Inc. now owns 2,481,257 shares of the medical research company's stock valued at $1,372,157,000 after acquiring an additional 604,895 shares during the period. Finally, Dimensional Fund Advisors LP boosted its position in Thermo Fisher Scientific by 1.2% during the second quarter. Dimensional Fund Advisors LP now owns 1,740,482 shares of the medical research company's stock worth $962,482,000 after purchasing an additional 20,075 shares during the period. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the stock. Morgan Stanley raised their target price on shares of Thermo Fisher Scientific from $655.00 to $680.00 and gave the stock an "overweight" rating in a research note on Friday, September 20th. Robert W. Baird reduced their price objective on Thermo Fisher Scientific from $632.00 to $622.00 and set an "outperform" rating for the company in a report on Thursday, October 24th. Raymond James increased their target price on Thermo Fisher Scientific from $650.00 to $660.00 and gave the stock an "outperform" rating in a research note on Thursday, July 25th. UBS Group raised Thermo Fisher Scientific to a "strong-buy" rating in a report on Monday, September 16th. Finally, Barclays dropped their target price on Thermo Fisher Scientific from $620.00 to $610.00 and set an "equal weight" rating for the company in a report on Wednesday, October 23rd. Four equities research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Thermo Fisher Scientific presently has an average rating of "Moderate Buy" and a consensus price target of $649.33.

Thermo Fisher Scientific Price Performance

Shares of TMO stock traded up $0.23 on Wednesday, reaching $509.35. The company had a trading volume of 796,278 shares, compared to its average volume of 1,488,421. The business's 50-day moving average is $581.75 and its 200 day moving average is $581.46. The stock has a market capitalization of $194.83 billion, a PE ratio of 31.92, a price-to-earnings-growth ratio of 3.39 and a beta of 0.79. Thermo Fisher Scientific Inc. has a one year low of $476.45 and a one year high of $627.88. The company has a quick ratio of 1.26, a current ratio of 1.63 and a debt-to-equity ratio of 0.64.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its quarterly earnings results on Wednesday, October 23rd. The medical research company reported $5.28 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.25 by $0.03. Thermo Fisher Scientific had a net margin of 14.48% and a return on equity of 17.49%. The company had revenue of $10.60 billion during the quarter, compared to the consensus estimate of $10.63 billion. During the same period in the prior year, the business earned $5.69 earnings per share. The company's revenue for the quarter was up .2% compared to the same quarter last year. Equities research analysts forecast that Thermo Fisher Scientific Inc. will post 21.67 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, January 15th. Shareholders of record on Friday, December 13th will be given a $0.39 dividend. This represents a $1.56 annualized dividend and a yield of 0.31%. The ex-dividend date is Friday, December 13th. Thermo Fisher Scientific's dividend payout ratio (DPR) is currently 9.78%.

Thermo Fisher Scientific declared that its Board of Directors has authorized a stock buyback plan on Friday, November 15th that allows the company to repurchase $4.00 billion in outstanding shares. This repurchase authorization allows the medical research company to buy up to 2% of its shares through open market purchases. Shares repurchase plans are often an indication that the company's board believes its shares are undervalued.

Insider Transactions at Thermo Fisher Scientific

In other news, CEO Marc N. Casper sold 9,000 shares of the stock in a transaction dated Friday, November 8th. The shares were sold at an average price of $552.86, for a total transaction of $4,975,740.00. Following the transaction, the chief executive officer now owns 14,608 shares of the company's stock, valued at $8,076,178.88. This represents a 38.12 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Gianluca Pettiti sold 300 shares of the stock in a transaction that occurred on Friday, October 25th. The stock was sold at an average price of $560.16, for a total value of $168,048.00. Following the completion of the transaction, the executive vice president now owns 16,663 shares in the company, valued at approximately $9,333,946.08. The trade was a 1.77 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 37,150 shares of company stock worth $20,651,865. Company insiders own 0.34% of the company's stock.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.